Premium
Adjuvant chemotherapy with fluorouracil, doxorubicin, and cyclophosphamide, with or without Bacillus Calmette‐Guerin and with or without irradiation in operable breast cancer a prospective randomized trial
Author(s) -
Buzdar Aman U.,
Blumenschein George R.,
Smith Terry L.,
Powell Kimberly C.,
Hortobagyi Gabriel N.,
Yap Hwee Y.,
Schell Frank C.,
Barnes Brian C.,
Ames Frederick C.,
Martin Richard G.,
Hersh Evan M.
Publication year - 1984
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/1097-0142(19840201)53:3<384::aid-cncr2820530303>3.0.co;2-g
Subject(s) - medicine , cyclophosphamide , adjuvant , chemotherapy , fluorouracil , breast cancer , randomization , surgery , randomized controlled trial , doxorubicin , immunotherapy , cancer , oncology , gastroenterology
Between May 1977 and April 1980, 238 patients with operable breast cancer were treated with adjuvant fluorouracil, doxorubicin, and cyclophosphamide (FAC) chemotherapy. All patients were randomized to receive FAC alone or FAC with nonspecific immunotherapy with Bacillus Calmette‐Guerin (BCG) vaccine. A randomization for routine postoperative irradiation was included in the study in May 1978. At the median follow‐up of 33 months, 53 patients had developed recurrent disease. Up to the present time, there have been no significant differences in the disease‐free survival of patients treated with FAC alone from those treated with FAC + BCG ( P = 0.21). The disease‐free survival for patients treated with and without routine postoperative irradiation was similar ( P = 0.99). Disease‐free survival of premenopausal and postmenopausal women was similar. The overall estimate of disease‐free survival was 72% at 3 years.